Loading
A phase 3 trial of Datopotamab deruxtecan, Pembrolizumab, Pemetrexed in non-small-cell lung cancer and small-cell lung cancer, run by Daiichi Sankyo, active and no longer recruiting.
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) is a phase 3 interventional study registered as NCT05555732 by Daiichi Sankyo, with 1170 participants planned, started 2023-01-11 and due to reach its primary completion in 2029-05-11. Interventions recorded: Datopotamab Deruxtecan, Pembrolizumab, Pemetrexed, Carboplatin, Cisplatin. Conditions listed: Metastatic Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Datopotamab deruxtecan, Pemetrexed, Topoisomerase-I inhibitors (and ADC payloads), Cisplatin.
Shares Daiichi Sankyo, Pemetrexed, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Pemetrexed, Topoisomerase-I inhibitors (and ADC payloads), Cisplatin, Carboplatin.
Shares Pemetrexed, Topoisomerase-I inhibitors (and ADC payloads), Cisplatin, Carboplatin.
Shares Datopotamab deruxtecan, Pemetrexed, Topoisomerase-I inhibitors (and ADC payloads), Cisplatin.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Datopotamab deruxtecan, Daiichi Sankyo, Small-cell lung cancer, Pembrolizumab.